Every Form 4 that Kewaunee Scientific Corp (KEQU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KEQU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KEQU filings page.
Kewaunee Scientific senior vice president of People & Culture Elizabeth D. Phillips reported compensation-related stock transactions. On June 30, 2026, she exercised restricted stock units, acquiring 6,656 shares of common stock. Of these, 793 shares were withheld at $36.25 per share to cover tax obligations.
Footnotes state that performance-based RSUs vested at 150% of target, with RSUs otherwise entitling her to 4,995 shares settled in cash through a disposition to the issuer at $36.25 per share, while 475 service-based RSUs delivered 475 shares. After these transactions, she directly holds 9,116 shares of common stock.
Kewaunee Scientific senior vice president of IT & Engineering Mandar Ranade reported several equity compensation transactions dated June 30, 2026. He exercised awards to acquire 7,227 shares of common stock at a stated price of $0.0000 per share, tied to vested restricted stock units. Footnotes explain that 4,159 shares were delivered upon settlement of service- and performance-based RSUs, while an additional portion of performance-based RSUs was settled in cash in lieu of 1,800 shares. To cover obligations, 1,877 shares were disposed of at $36.25 per share as a tax-withholding transaction and 1,800 shares were returned to the company at the same price as a disposition to the issuer. After these moves, Ranade directly holds 16,215 shares of common stock.
Kewaunee Scientific senior vice president of sales and marketing development Ryan S. Noble reported several equity compensation transactions in the company’s common stock. On June 30, 2026, he exercised awards to acquire 7,206 shares of common stock, primarily from vested restricted stock units. To cover obligations tied to this settlement, 1,809 shares were used in a tax-withholding disposition at $36.25 per share, and 3,000 shares were delivered back to the issuer as a disposition to the company at the same price. After these transactions, Noble directly held 16,240 shares of common stock. He also continued to hold unvested or unsettled restricted stock units from more recent grants, including FY25 and FY26 awards that are subject to service-based and performance-based vesting conditions.
Kewaunee Scientific senior vice president of manufacturing operations Douglas J. Batdorff reported a set of compensation-related equity transactions. On June 30, 2026, he acquired 7,451 shares of common stock through the settlement of restricted stock units, while 851 shares were withheld to cover tax obligations and 5,609 shares were disposed of back to the company for cash instead of receiving shares. Footnotes note that 3,739 performance-based RSUs vested at 150% of target and 535 service-based RSUs vested the same day.
Kewaunee Scientific Chief Financial Officer Donald T. Gardner III reported a series of equity compensation events on June 30, 2026. He exercised and settled various restricted stock units into common stock, including performance-based RSUs that vested at 150% of target. As part of the settlement, 4,027 shares of common stock at $36.25 per share were withheld to cover tax obligations, and 12,000 shares were delivered to the company pursuant to his prior election for cash settlement. Footnotes state that, in total, 11,397 performance-based RSUs were settled and 6,723 shares were received from RSU settlements, along with a cash payment in lieu of additional shares.
Kewaunee Scientific President and CEO Thomas David Hull III reported several compensation-related share transactions tied to restricted stock units. On June 30, 2026, he exercised or settled awards to acquire common stock and used part of the shares to cover obligations.
Hull exercised or settled awards covering 54,388 shares of common stock. Of these, 16,243 shares were delivered at $36.25 per share to satisfy tax obligations, and 17,000 shares were disposed to the issuer for cash under his election. Footnotes state that service- and performance-based RSUs convert one-for-one into common stock.
Footnotes also explain that 28,929 performance-based RSUs were settled at 150% of target, resulting in 26,393 shares plus cash in lieu of 17,000 shares, and 4,132 service-based RSUs vested. Overall, the filing reflects routine equity compensation vesting, tax withholding, and related dispositions rather than open-market trading.
Phillips Elizabeth D reported acquisition or exercise transactions in this Form 4 filing.
KEWAUNEE SCIENTIFIC CORP senior vice president of People & Culture, Elizabeth D. Phillips, received a compensation grant of 2,466 restricted stock units tied to the company’s common stock. Each unit represents a contingent right to one share and will vest in three equal annual installments beginning on June 30, 2027, subject to her continued employment. Following this award, her reported holdings from this grant total 2,466 units.
Ranade Mandar reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific senior vice president of IT & Engineering Mandar Ranade received a grant of 2,635 restricted stock units tied to the company’s common stock. Each unit represents a right to one share. The award will vest in three equal annual installments beginning on June 30, 2027, contingent on continued employment.
Noble Ryan S. reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific reported that senior vice president of Sales & Marketing Development Ryan S. Noble received a grant of 2,628 Restricted Stock Units (RSUs) for FY27 on June 24, 2026. Each RSU represents a contingent right to receive one share of common stock. The RSUs vest in three equal annual installments beginning June 30, 2027, subject to his continued employment with the company. Following this compensation-related award, Noble holds 2,628 RSUs linked to Kewaunee Scientific common stock.
Batdorff Douglas J. reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific senior vice president of manufacturing operations Douglas J. Batdorff received a grant of 2,717 restricted stock units tied to the company’s common stock. Each unit represents a right to one share. Following this grant, he holds 2,717 restricted stock units directly.
The award will vest in three equal annual installments beginning on June 30, 2027, and is contingent on his continued employment with the company. This is a compensation-related equity grant rather than an open-market stock purchase or sale.
Gardner Donald T. III reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific reported that Chief Financial Officer Donald T. Gardner III received a compensation-related grant of derivative securities. He was awarded 5,428 restricted stock units linked to the company’s common stock, with each unit representing the right to receive one share in the future.
The restricted stock units will vest in three equal annual installments beginning on June 30, 2027, conditioned on his continued employment with the company. Following this grant, his reported holding of these FY27 restricted stock units is 5,428 units.
HULL THOMAS DAVID III reported acquisition or exercise transactions in this Form 4 filing.
KEWAUNEE SCIENTIFIC CORP President & CEO Thomas David Hull III reported an equity compensation grant in the form of restricted stock units. He received 15,195 RSUs tied to the company’s common stock, each representing a contingent right to one share, with no cash paid per unit.
The RSUs will vest in three equal annual installments starting on June 30, 2027, as long as he remains employed by the company. Following this award, his reported holdings for this RSU grant total 15,195 units directly.
Campbell John Jette reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director John Jette Campbell received an equity grant of 2,013 shares of Common Stock as part of his annual compensation. The shares were awarded at no cash cost under the company’s 2023 Omnibus Incentive Plan, increasing his directly held position to 2,703 shares after the award.
GEHL KEITH M reported acquisition or exercise transactions in this Form 4 filing.
Kewaunee Scientific director Keith M. Gehl received a grant of 2,013 shares of Common Stock on May 1, 2026. The shares were awarded under the company’s 2023 Omnibus Incentive Plan as the equity portion of his annual compensation and were granted at $0.00 per share. Following this award, he directly holds 22,409 shares of Kewaunee Scientific common stock.
Kewaunee Scientific director Margaret B. Pyle reported a bona fide gift of 2,750 shares of common stock held indirectly through a trust. The shares were transferred on March 26, 2026, as a gift to five grandchildren, with no sale proceeds involved. After the transfer, trust-related indirect holdings reported for her total 36,891 shares, and a separate 5,000 shares are reported as held indirectly by her spouse.
Kewaunee Scientific Corporation’s President and CEO, Thomas David Hull III, who is also a director, reported a sale of company stock. On 01/07/2026, he sold 2,177 shares of Common Stock, reported at a weighted average price of $37.5 per share. The shares were sold in multiple trades at prices ranging from $37.21 to $37.54. After this transaction, he beneficially owns 33,000 shares of Kewaunee Scientific common stock directly.
Kewaunee Scientific Corporation Chief Financial Officer Donald T. Gardner III reported an open-market sale of 2,000 shares of common stock on January 6, 2026. The shares were sold at a weighted average price of $37.57, with individual trade prices ranging from $37.50 to $38.00.
Following this transaction, Gardner beneficially owned 9,564 shares of Kewaunee Scientific common stock in direct ownership. He has undertaken to provide, upon request, detailed information about the number of shares sold at each separate price within the reported range.
Kewaunee Scientific insider activity shows its President and CEO, who also serves as a director, reported a stock sale. On 12/17/2025, the reporting person sold 1,000 shares of Kewaunee Scientific common stock at a price of $39 per share. After this transaction, the insider beneficially owns 37,719 shares directly.
Donald T. Gardner III, Chief Financial Officer and director, reported a sale of 3,000 shares of Kewaunee Scientific Corp (KEQU) on 10/09/2025 at a weighted average price of $42.76 per share. After the transactions, he beneficially owned 11,564 shares. The filing states the sale occurred in multiple trades priced between $42.68 and $43.57, and the reporting person offered to provide a breakdown of shares sold at each price upon request. The Form 4 is signed and dated 10/10/2025, indicating timely disclosure of the insider transaction.
Elizabeth D. Phillips, listed as a director and Vice President - Human Resources of Kewaunee Scientific Corp (KEQU), reported insider sales on 10/02/2025. The filing shows a sale of 6,877 shares at a weighted-average price of $43.20 (price range $43.05–$43.95), followed by an additional sale of 3 shares at $44.20. After the transactions the reporting person beneficially owned 8,251 shares and then 8,248 shares (direct ownership). The Form 4 was signed by an attorney-in-fact, Donald T. Gardner III. The filer also states availability of per-price purchase breakdown upon request.
Kewaunee Scientific director and President/CEO Thomas David Hull III reported a sale of 1,000 shares of the company's common stock on 10/01/2025 at a weighted average price of $43.09 per share, with the reported price range between $43.00 and $43.22. Following the sale, Mr. Hull beneficially owns 38,719 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. The filing includes a statement that the reporting person will provide, upon request, the number of shares bought at each separate price within the disclosed range.
KEWAUNEE SCIENTIFIC CORP (/DE/, KEQU) reporting person Thomas David Hull III, who serves as President, CEO and a director, reported a sale of common stock on 09/29/2025. The Form 4 shows 1,854 shares were sold at a weighted average price of $43.42, with the trade price range disclosed as $43.00 to $43.85. After the sale, Hull beneficially owns 39,719 shares, held directly. The form was signed by an attorney-in-fact on 10/01/2025. The filing includes an undertaking to provide detailed per-price purchase information on request.
Thomas David Hull III, President, CEO and director of Kewaunee Scientific Corp (KEQU), reported two open-market sales of common stock on September 23-24, 2025. He sold 721 shares on 09/23/2025 at a weighted-average price shown as $44 and an additional 1,000 shares on 09/24/2025 at a weighted-average price shown as $43.62. After the September 23 trade his beneficial ownership was 42,573 shares and after the September 24 trade it was 41,573 shares. The form was signed by an attorney-in-fact on 09/24/2025. The filing includes a note that reported prices are weighted averages and that the filer will provide breakdowns on request.
Thomas David Hull III, who serves as President, CEO and a director of Kewaunee Scientific Corp (KEQU), reported two insider sales of common stock on September 18 and 19, 2025. On 09/18/2025 he sold 652 shares at a weighted average price of $46 (price range $46.00–$46.03), leaving him with 44,067 shares beneficially owned after that transaction. On 09/19/2025 he sold 773 shares at a weighted average price of $45.34 (price range $45.21–$45.71), with 43,294 shares reported beneficially owned following that sale. The Form 4 was executed by an attorney-in-fact and includes standard explanatory remarks about weighted average pricing.